Exploring impact of mutations in non-BRCA DNA damage response (DDR) and non-DDR genes on efficacy in phase III EMBRACA study of talazoparib (TALA) in patients (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) advanced breast cancer (ABC).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jennifer Keating Litton, Douglas Laird, Hope S. Rugo, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri Roche, Young-Hyuck Im, Annabel Goodwin, Joanne Lorraine Blum, Wolfgang Eiermann, Ying Chen, Silvana Lanzalone, Jijumon Chelliserry, Akos Czibere, Lee A. Albacker, Garrett M. Frampton, Lida A. Mina
Institutions: The University of Texas MD Anderson Cancer Center, Pfizer (United States), University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, TUM Klinikum, Technical University of Munich, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Universidad Complutense de Madrid, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Investigación Sanitaria Gregorio Marañón, Institut universitaire du cancer de Toulouse Oncopole, Samsung Medical Center, The University of Sydney, The US Oncology Network, Foundation Medicine (United States), Banner MD Anderson Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W3030554218